NCT03134417

Magnesium and Vitamin D Supplementation and Cardiometabolic Outcomes

Parathyroid Hormone and Cardiometabolic Outcomes in Obesity: Role of Magnesium and Vitamin D Supplementation

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 109 (actual)
• Sponsor: Drexel University · Academic / Other
• Sex: All
• Age: 30 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the effects of a combined vitamin D and magnesium supplementation on parathyroid hormone and cardiometabolic health in persons living with obesity.

Detailed description

Individuals living with obesity are at a higher risk of cardiometabolic abnormalities and high circulating parathyroid hormone. There is evidence suggesting that vitamin D may play a role in cardiovascular health outcomes; however, the research is currently inconclusive. Magnesium is a cofactor of vitamin D metabolism, and the prevalence of concurrent vitamin D and magnesium deficiency is high. This study aims to investigate the effect of vitamin D and magnesium supplements in individuals who are overweight and obese on parathyroid hormone and cardiometabolic health.

Conditions

• Overweight and Obesity
• Vitamin D Deficiency
• Magnesium Deficiency
• Cardiovascular Risk Factor

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Vitamin D and magnesium	Daily vitamin D and magnesium supplements are given to participants daily for 12 weeks.
DIETARY_SUPPLEMENT	Vitamin D	Daily vitamin D supplements are given to participants daily for 12 weeks.
DIETARY_SUPPLEMENT	Placebo	Daily placebo are given to participants daily for 12 weeks.

Timeline

• Start date: 2016-02-01
• Primary completion: 2020-12-31
• Completion: 2021-06-01
• First posted: 2017-05-01
• Last updated: 2021-09-27

Locations

1 site across 1 country: United States